David Matthew T. - 14 Oct 2026 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Reporting relationship: Chief Financial Officer
Issuer ticker: ATNM
Reported as of: 14 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Oct 2026, 17:11:10 UTC
Prior SEC filing: 14 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew T David

Filing notes and source

Key filing fact

David Matthew T. filed Form 4 for Actinium Pharmaceuticals, Inc. (ATNM) on 16 Oct 2026.

Key facts

This page summarizes David Matthew T.'s Form 4 filing for Actinium Pharmaceuticals, Inc. (ATNM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Oct 2026, 17:11.

Change

Previous filing in this sequence was filed on 14 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001811612 Primary reporting owner

David Matthew T

Relationship: Chief Financial Officer
Address: 100 PARK AVENUE, 23RD FLOOR, NEW YORK
Signature: /s/ Matthew T David
Signature date: 16 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNM transaction

Common Stock

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 14 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNM transaction Derivative

Stock Option (right to purchase)

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 14 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $0.9750
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On October 14, 2026 (the "Grant Date"), Mr. David was granted two hundred fifty thousand (250,000) Restricted Stock Units ("RSUs") under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan (the "Inducement Plan"). One hundred twenty-five thousand (125,000) RSUs shall vest in three (3) equal installments on each of the first, second, and third anniversaries of the Grant Date, subject to Mr. David's continuing service to the Issuer on each the applicable vesting date. One hundred twenty-five thousand (125,000) RSUs shall vest in full on the third (3rd) anniversary of the Grant Date, subject to Mr. David's continuing service to the Issuer on the applicable vesting date.

Footnote F2

On the Grant Date, Mr. David was granted the option to purchase 250,000 shares of common stock (the "Option Grant") of Actinium Pharmaceuticals, Inc. (the "Issuer") under the Inducement Plan.

Footnote F3

Twenty-eight percent (28%) of the Option Grant shall vest twelve (12) months after the Grant Date and two percent (2%) of the Option Grant shall vest each month thereafter, subject to Mr. David's continuing service to the Issuer on each application vesting date.